Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 519

Sort by

Sort Order Select

Journal Articles

Role of allo-HCT in "nonclassical" MPNs and MDS/MPNs: recommendations from the PH&G Committee and the CMWP of the EBMT

Nicola Polverelli, Juan Carlos Hernandez-Boluda, Francesco Onida, Carmelo Gurnari, Kavita Raj, Tomasz Czerw, Michelle Kenyon, Marie Robin, Katja Sockel, Annalisa Ruggeri, Isabel Sánchez-Ortega, Daniel A. Arber, Luca Arcaini, Fernando Barroso Duarte, Giorgia Battipaglia, Yves Chalandon, Fabio Ciceri, Nicholas C.P. Cross, Joanna Drozd-Sokolowska, Vaneuza Araújo Moreira Funke, Nico Gagelmann, Naseema Gangat, Jason Gotlib, Paola Guglielmelli, Claire N. Harrison, Gabriela S Hobbs, Tania Jain, Joseph D. Khoury, Jean-Jacques Kiladjian, Nicolaus Kröger, Luca Malcovati, Massimo Martino, Ruben Mesa, Attilio Orazi, Eric Padron, Francesca Palandri, Francesco Passamonti, Mrinal M. Patnaik, Naveen Pemmaraju, Deepti H. Radia, Andreas Reiter, Domenico Russo, Christof Scheid, Ayalew Tefferi, Alessandro M. Vannucchi, Daniel Howard Wiseman, Ibrahim Yakoub-Agha, Donal P McLornan

Blood blood.2024028000.

https://doi.org/10.1182/blood.2024028000

Published: 2025

Includes: Supplemental data

Journal Articles

Blastic plasmacytoid dendritic cell neoplasm in the absence of cutaneous involvement

Naveen Pemmaraju, Sanam Loghavi

Blood (2025) 145 (8): 898.

https://doi.org/10.1182/blood.2024027086

Published: 2025

Journal Articles

How I treat blastic plasmacytoid dendritic cell neoplasm

Mohamed A. Kharfan-Dabaja, Andrew A. Lane, Naveen Pemmaraju

Blood (2025) 145 (6): 567–576.

https://doi.org/10.1182/blood.2024024262

Published: 2025

Journal Articles

Preclinical efficacy of CDK7 inhibitor–based combinations against myeloproliferative neoplasms transformed to AML

Blood (2025) 145 (6): 612–624.

https://doi.org/10.1182/blood.2024026388

Published: 2025

Includes: Supplemental data

Journal Articles

Safety and Efficacy of G-CSF with Intensive Chemotherapy in Newly Diagnosed Acute Myeloid Leukemia: A Subgroup Analysis of the Phase II Trial of Venetoclax in Combination with Cladribine, Idarubicin, and Cytarabine

Blood (2024) 144 (Supplement 1): 446.

https://doi.org/10.1182/blood-2024-203938

Published: 2024

Journal Articles

Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) International Registry: Tagraxofusp Cohort Treatment Results

Blood (2024) 144 (Supplement 1): 2870.

https://doi.org/10.1182/blood-2024-210872

Published: 2024

Journal Articles

Phase 1b/2 Study of Magrolimab (Magro), Azacitidine (AZA) and Venetoclax (VEN) in Patients (pts) with Newly Diagnosed (ND) Older/Unfit or High Risk Acute Myeloid Leukemia (AML) and Relapsed Refractory (R/R) AML: Final Clinical Data and Genomic Markers of Resistance/Relapse

Blood (2024) 144 (Supplement 1): 735.

https://doi.org/10.1182/blood-2024-203706

Published: 2024

Journal Articles

A Phase II Trial of Venetoclax in Combination with Cladribine, Idarubicin, and Cytarabine in Newly Diagnosed Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndrome

Blood (2024) 144 (Supplement 1): 734.

https://doi.org/10.1182/blood-2024-203459

Published: 2024

Journal Articles

Establishing Benchmarks for Relapse-Free and Overall Survival Among Patients (Pts) with Newly Diagnosed AML Not Undergoing Allogeneic Stem Cell Transplantation (SCT) in First Remission

Eitan Kugler, Hagop M. Kantarjian, Alexandre Bazinet, Wei-Ying Jen, Naval Daver, Courtney D. DiNardo, Nicholas J. Short, Jayastu Senapati, Gautam Borthakur, Naveen Pemmaraju, Ghayas C. Issa, Alex Bataller, Patrick K. Reville, Guillermo Garcia-Manero, Farhad Ravandi, Tapan M. Kadia

Blood (2024) 144 (Supplement 1): 2861.

https://doi.org/10.1182/blood-2024-199903

Published: 2024

Journal Articles

Clinical Outcomes Associated with NPM1 Mutations in Newly Diagnosed AML

Blood (2024) 144 (Supplement 1): 2853.

https://doi.org/10.1182/blood-2024-205504

Published: 2024

Journal Articles

Treatment Intensity in Acute Myeloid Leukemia with Extramedullary Disease

Blood (2024) 144 (Supplement 1): 2851.

https://doi.org/10.1182/blood-2024-202429

Published: 2024

Journal Articles

Clonal Origin of Therapy-Related Myeloid Neoplasms after Autologous Stem Cell Transplant

Blood (2024) 144 (Supplement 1): 346.

https://doi.org/10.1182/blood-2024-208106

Published: 2024

Journal Articles

Efficacy of a Novel BCL-XL Degrader, DT2216, in Preclinical Models of Post-Myeloproliferative Neoplasm Secondary AML

Blood (2024) 144 (Supplement 1): 2749.

https://doi.org/10.1182/blood-2024-194031

Published: 2024

Journal Articles

A Phase II Trial of Azacitidine with Ipilimumab, Nivolumab, or Ipilimumab and Nivolumab with or without Azacitidine in Relapsed or Refractory Myelodysplastic Syndrome

Blood (2024) 144 (Supplement 1): 3212.

https://doi.org/10.1182/blood-2024-205186

Published: 2024

Journal Articles

Combination Therapy with Nelarabine, Peg-Asparaginase and Venetoclax for Adults Patients with Relapsed/Refractory T-Cell ALL

Niranjan Shiwaji Khaire, Elias Jabbour, Tapan M. Kadia, Nicholas J. Short, Gautam Borthakur, Naveen Pemmaraju, Naval Daver, Partow Kebriaei, Shilpa Paul, Vishrut Shah, Rebecca Garris, Koji Sasaki, Farhad Ravandi, Nitin Jain

Blood (2024) 144 (Supplement 1): 4207.

https://doi.org/10.1182/blood-2024-206697

Published: 2024

Journal Articles

A Phase Ib, Open-Label Study of Add on Therapy with CK0804 in Participants with Myelofibrosis and Suboptimal Response to Ruxolitinib

Lucia Masarova, Meixian Huang, Swati Goel, Sharon Bledsoe, Naveen Pemmaraju, Tapan M. Kadia, Prithviraj Bose, Jo Ishizawa, Guillermo Montalban-Bravo, Mi-Ae Lyu, Tara Sadeghi, Simrit Parmar, Christopher R. Flowers, Hagop M. Kantarjian

Blood (2024) 144 (Supplement 1): 999.

https://doi.org/10.1182/blood-2024-211587

Published: 2024

Journal Articles

Phase I/II Study of the All-Oral Combination of Revumenib (SNDX-5613) with Decitabine/Cedazuridine (ASTX727) and Venetoclax (SAVE) in R/R AML

Blood (2024) 144 (Supplement 1): 216.

https://doi.org/10.1182/blood-2024-204375

Published: 2024

Journal Articles

Combined Pirtobrutinib, Venetoclax, and Obinutuzumab As First-Line Treatment of Patients with Chronic Lymphocytic Leukemia (CLL)

Blood (2024) 144 (Supplement 1): 1011.

https://doi.org/10.1182/blood-2024-211454

Published: 2024

Journal Articles

Updated Results from a Phase II Study of Vibecotamab, a CD3-CD123 Bispecific T-Cell Engaging Antibody, for MDS or CMML after Hypomethylating Failure and in MRD-Positive AML

Blood (2024) 144 (Supplement 1): 1007.

https://doi.org/10.1182/blood-2024-208684

Published: 2024

Journal Articles

Phase 2 Multicenter Trial of Tagraxofusp in Combination with Venetoclax and Azacitidine in Adults with Previously Untreated CD123+ Acute Myeloid Leukemia Ineligible for Intensive Chemotherapy

Naval Daver, Naveen Pemmaraju, Mikkael A. Sekeres, Amir T. Fathi, Andrew A. Lane, Anna Compagnoni, Ira Gupta, Alessandra Tosolini, Jessica Garzon, Hagop M. Kantarjian

Blood (2024) 144 (Supplement 1): 4265.1.

https://doi.org/10.1182/blood-2024-193593

Published: 2024

NARROW

Role of allo-HCT in "nonclassical" MPNs and MDS/MPNs: recommendations from the PH&G Committee and the CMWP of the EBMT

Blastic plasmacytoid dendritic cell neoplasm in the absence of cutaneous involvement

How I treat blastic plasmacytoid dendritic cell neoplasm

Preclinical efficacy of CDK7 inhibitor–based combinations against myeloproliferative neoplasms transformed to AML

Safety and Efficacy of G-CSF with Intensive Chemotherapy in Newly Diagnosed Acute Myeloid Leukemia: A Subgroup Analysis of the Phase II Trial of Venetoclax in Combination with Cladribine, Idarubicin, and Cytarabine

Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) International Registry: Tagraxofusp Cohort Treatment Results

Phase 1b/2 Study of Magrolimab (Magro), Azacitidine (AZA) and Venetoclax (VEN) in Patients (pts) with Newly Diagnosed (ND) Older/Unfit or High Risk Acute Myeloid Leukemia (AML) and Relapsed Refractory (R/R) AML: Final Clinical Data and Genomic Markers of Resistance/Relapse

A Phase II Trial of Venetoclax in Combination with Cladribine, Idarubicin, and Cytarabine in Newly Diagnosed Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndrome

Establishing Benchmarks for Relapse-Free and Overall Survival Among Patients (Pts) with Newly Diagnosed AML Not Undergoing Allogeneic Stem Cell Transplantation (SCT) in First Remission

Clinical Outcomes Associated with NPM1 Mutations in Newly Diagnosed AML

Treatment Intensity in Acute Myeloid Leukemia with Extramedullary Disease

Clonal Origin of Therapy-Related Myeloid Neoplasms after Autologous Stem Cell Transplant

Efficacy of a Novel BCL-XL Degrader, DT2216, in Preclinical Models of Post-Myeloproliferative Neoplasm Secondary AML

A Phase II Trial of Azacitidine with Ipilimumab, Nivolumab, or Ipilimumab and Nivolumab with or without Azacitidine in Relapsed or Refractory Myelodysplastic Syndrome

Combination Therapy with Nelarabine, Peg-Asparaginase and Venetoclax for Adults Patients with Relapsed/Refractory T-Cell ALL

A Phase Ib, Open-Label Study of Add on Therapy with CK0804 in Participants with Myelofibrosis and Suboptimal Response to Ruxolitinib

Phase I/II Study of the All-Oral Combination of Revumenib (SNDX-5613) with Decitabine/Cedazuridine (ASTX727) and Venetoclax (SAVE) in R/R AML

Combined Pirtobrutinib, Venetoclax, and Obinutuzumab As First-Line Treatment of Patients with Chronic Lymphocytic Leukemia (CLL)

Updated Results from a Phase II Study of Vibecotamab, a CD3-CD123 Bispecific T-Cell Engaging Antibody, for MDS or CMML after Hypomethylating Failure and in MRD-Positive AML

Phase 2 Multicenter Trial of Tagraxofusp in Combination with Venetoclax and Azacitidine in Adults with Previously Untreated CD123+ Acute Myeloid Leukemia Ineligible for Intensive Chemotherapy

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only